| GNMLF Stock | | | USD 1.27 0.00 0.00% |
Insider
Alejandro Patio is Media, Relations of Genomma Lab Internacional
| Phone | 52 55 5081 0000 |
| Web | https://www.genommalab.com |
Genomma Lab Management Efficiency
The company has return on total asset
(ROA) of
0.0921 % which means that it generated a profit of $0.0921 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.1264 %, meaning that it generated $0.1264 on every $100 dollars invested by stockholders. Genomma Lab's management efficiency ratios could be used to measure how well Genomma Lab manages its routine affairs as well as how well it operates its assets and liabilities.
Genomma Lab Internacional has accumulated 3.83
B in total debt with debt to equity ratio
(D/E) of 0.51, which is about average as compared to similar companies. Genomma Lab Internacional has a current ratio of 1.64, which is within standard range for the sector. Debt can assist Genomma Lab until it has trouble settling it off, either with new capital or with free cash flow. So, Genomma Lab's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Genomma Lab Internacional sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Genomma to invest in growth at high rates of return. When we think about Genomma Lab's use of debt, we should always consider it together with cash and equity.
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, engages in the development, marketing, and sale of over-the-counter pharmaceutical and personal care products in Mexico and internationally. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico. Genomma Lab operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 2327 people. Genomma Lab Internacional [GNMLF] is a
Pink Sheet which is traded through a dealer network over-the-counter (OTC).
Management Performance
Genomma Lab Internacional Leadership Team
Elected by the shareholders, the Genomma Lab's board of directors comprises two types of representatives: Genomma Lab inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genomma. The board's role is to monitor Genomma Lab's management team and ensure that shareholders' interests are well served. Genomma Lab's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genomma Lab's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Efran Crdova, Deputy Sec | |
| Engineer Galland, Exec CFO | |
| Marianne Velasco, Global HR | |
| Mximo Juda, Advisor | |
| L Porres, Legal Officer | |
| Daniel Neria, Head Relations | |
| Jorge Valderrama, Chief Officer | |
| Juan Sparvieri, Ex COO | |
| Alejandro Patio, Media, Relations | |
Genomma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Genomma Lab a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Genomma Pink Sheet
Genomma Lab financial ratios help investors to determine whether Genomma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Genomma with respect to the benefits of owning Genomma Lab security.